MLH1 and neoplasm: Patients with clinical suspicion of Lynch syndrome, but without a germline mutation in an MMR gene or a familiar history of cancer, typically show aberrant methylation of the MLH1 promoter in normal and tumor tissues, suggesting that it is a causative agent for cancer development in these people [72].